• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Using RWD to Unlock Better Outcomes for IBD and NASH Patients



Thu, Jul 28, 2022 11:00 AM EDT With no cure for IBD and other conditions, like NASH, treatments are aimed at reducing symptoms and preventing complications. Real-world data and AI applications provide a unique opportunity to better understand disease progression, treatment effectiveness, and outcomes.

Register Free: https://www.pharmexec.com/pe_w/unlock-better

Event Overview:

Gastrointestinal and metabolic disorders are highly prevalent and result in reduced quality of life for many patients. With no cure for inflammatory bowel disease (IBD) and other conditions, like non-alcoholic steatohepatitis (NASH), treatments are aimed at reducing symptoms and preventing complications and progression. More research is needed to better understand natural history and progression, treatment effectiveness, and outcomes.
Linked real-world data (RWD) and machine learning (ML) applications provide a unique opportunity to support clinical development, real-world evidence, and commercialization strategies. Join this webinar to explore how they can be used to:

  • Gain insights into disease progression and condition subtypes
  • Understand treatment response and gaps in care
  • Identify and validate under-diagnosed and high-risk patients

Key Learning Objectives:

At the end of this presentation participants will be able to:

  • Discuss opportunities for using real-world datasets in GI and metabolic conditions
  • Identify applications for artificial intelligence in real-world data analyses and evaluating outcomes
  • Explore use cases for generating insights and evidence

Who Should Attend:

  • Life sciences companies developing treatments for gastroenterology and metabolic conditions, such as Crohn’s disease, ulcerative colitis, and NASH.
  • Senior managers and executives in R&D, clinical operations, clinical affairs, medical affairs, market access, commercial, HEOR, real-world data, real-world evidence, strategy and innovation functions.


Dr. Gary Curhan, MD, ScD
Chief Medical Officer
Dr. Gary Curhan, MD, ScD, is the Chief Medical Officer of OM1, Inc. He is a practicing nephrologist in Boston.
Dr. Curhan has published widely on the epidemiology of many medical conditions, including cardiovascular disease, hypertension, kidney stones, gout, and hearing loss. His research in several large cohort studies, including the Nurses’ Health Studies and the Health Professionals Follow-Up Study, focuses on the prevention of common diseases by investigating scientifically and clinically important questions and exploring the role of modifiable factors, and has been supported continuously for over 25 years by the National Institutes of Health. He was the Editor-in-Chief of the Clinical Journal of the American Society of Nephrology, a leading nephrology journal. He has served on many national and international advisory committees, including the National Institutes of Health. He has mentored numerous individuals, many of whom now hold leadership positions at major academic institutions and public companies.

Register Free: https://www.pharmexec.com/pe_w/unlock-better

Related Content